Hemostatics
Hemostatics Pharmaceuticals S.L. is a Barcelona-based preclinical biotech developing CM-352, a patented intravenous antifibrinolytic agent for life-threatening hemorrhagic conditions including surgery, trauma, ICH, and rare bleeding disorders.
- Company typePrivate
- Founded2020
- HeadquartersBarcelona, Spain
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Hemostatics does
Hemostatics Pharmaceuticals S.L. is a Barcelona-based, preclinical-stage biotechnology company founded in August 2020 to develop CM-352, a novel small-molecule antifibrinolytic agent designed for intravenous administration. CM-352 inhibits fibrinolysis through a new mechanism of action and is being positioned to address life-threatening and disabling hemorrhagic conditions across at least six target indications: major surgery, trauma, intracerebral hemorrhage (ICH), gynecology-related bleeding, rare bleeding disorders, and gastrointestinal bleeding. Preclinical data reports an 89% reduction in bleeding time and a 61% reduction in blood loss in mouse models, with demonstrated efficacy in severe-bleeding scenarios where the incumbent antifibrinolytics TXA and aprotinin are reportedly ineffective.
The company operates with 1-10 employees and holds an IP portfolio of four granted patents (three on drug formulas, one on mechanism of action). Its asset originated at the Centro de Investigación Médica Aplicada (CIMA) at the University of Navarra in Pamplona, Spain, and is licensed exclusively to Hemostatics through Fundación para la Investigación Médica Aplicada (FIMA). Scientific collaborations are in place with the Spanish Society of Thrombosis and Haemostasis (SETH) and HealthTech180. Hemostatics has raised approximately $1.45M in disclosed funding across 2022 and 2024 rounds (investors undisclosed) and is currently fundraising to advance CM-352 toward Phase 1 clinical trials. The company has no commercial product, no disclosed revenue, and serves Western Europe as its operating geography.
Hemostatics firmographics
Firmographics- Name
- Hemostatics
- Legal name
- Hemostatics Pharmaceuticals S.L.
- Website
- https://hemostatics.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Hemostatics Pharmaceuticals S.L. is a Barcelona-based preclinical biotech developing CM-352, a patented intravenous antifibrinolytic agent for life-threatening hemorrhagic conditions including surgery, trauma, ICH, and rare bleeding disorders.
- Ownership category
- akta.pro rank
Hemostatics industry classification
Industry- Product category
- Antifibrinolytic Pharmaceuticals
- akta.pro primary industry
- Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL)
- akta.pro secondary industry
- Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor) (HLAIAHAF)
Keywords
Where Hemostatics is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
Hemostatics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Hemostatics product offering
Product offeringCore offering
Hemostatics is developing CM-352, a novel antifibrinolytic agent designed to reduce bleeding in life-threatening and disabling hemorrhagic conditions. The compound uses a new mechanism of action to inhibit fibrinolysis and is optimized for intravenous administration, targeting major surgery, trauma, intracerebral hemorrhage (ICH), gynecological bleeding, rare bleeding disorders, and gastrointestinal bleeding.
Product overview
Hemostatics is a biotechnology company developing a single unified pharmaceutical product: CM-352, a novel antifibrinolytic agent. CM-352 is supported by the company's patented technology platform that uses a new mechanism of action to inhibit fibrinolysis. The product candidate is in preclinical development and aims to address life-threatening and disabling hemorrhagic conditions including major surgery, trauma, intracranial hemorrhage (ICH), gynecological bleeding, rare bleeding disorders, and gastrointestinal bleeding.
Differentiator
Problem solved
Functional benefit
Products and services
- CM-352
Quantifiable outcome
- 89% reduction in bleeding time in mice at minimal effective dose (10 μg/kg)
- +5 more outcomes
Companies that use Hemostatics
Customer profileSegments6 records
Ideal customer profiles2 records
Hemostatics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Hemostatics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Fundación para la Investigación Médica Aplicada (FIMA)coreStrategic partnership and exclusive licensing agreement with FIMA, a not-for-profit foundation managing Centro de Investigación Médica Aplicada (CIMA). FIMA provided the core technology and intellectual property that Hemostatics is developing commercially. This is the foundational partnership that enabled the company's creation.
- Centro de Investigación Médica Aplicada (CIMA), University of NavarracoreCIMA is the biomedical research center of Clinica Universidad de Navarra in Pamplona, Spain. The research center developed the underlying technology that became CM-352. Hemostatics has an exclusive licensing arrangement with CIMA through FIMA for the development and commercialization of the antifibrinolytic technology.
- Sociedad Española de Trombosis y Hemostasia (SETH)minorSpanish Society of Thrombosis and Haemostasis - a professional medical society providing scientific expertise and collaboration in the field of hemostasis research. Partnership provides access to scientific expertise and clinical insights relevant to the development of antifibrinolytic therapies.
- HealthTech180minorHealthTech accelerator or consultancy providing healthcare technology expertise. Partnership suggests collaboration in advancing the technology development and potential commercialization strategy.
Scale indicators8 records
Recent moves5 records
Expansion highlights4 records
Hemostatics competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights6 records
Customer concentration
Hemostatics social profiles
Digital presenceHemostatics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hemostatics leadership team
Management profileNumber of profiles
Hemostatics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hemostatics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hemostatics
What does Hemostatics do?
Hemostatics is developing CM-352, a novel antifibrinolytic agent designed to reduce bleeding in life-threatening and disabling hemorrhagic conditions. The compound uses a new mechanism of action to inhibit fibrinolysis and is optimized for intravenous administration, targeting major surgery, trauma, intracerebral hemorrhage (ICH), gynecological bleeding, rare bleeding disorders, and gastrointestinal bleeding.
Is Hemostatics a public or private company?
Hemostatics is a private company. It is classified as unknown and is currently operating.
When was Hemostatics founded?
Hemostatics was founded in 2020. It employs 1 to 10 people.
Where is Hemostatics based?
Hemostatics is headquartered in Barcelona, Spain, in the Europe region.
Does Hemostatics have an API?
No public API is recorded for Hemostatics.
What industry is Hemostatics in?
Hemostatics's product category is Antifibrinolytic Pharmaceuticals. Its primary akta.pro industry code is HLAAAAAL, Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics), with a secondary code of HLAIAHAF, Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor).